AI Summary

Researchers have identified a protein that may be hindering the effectiveness of CAR T-cell therapy, a treatment for certain types of cancer. This protein, NFIL3, appears to cause engineered immune cells to become exhausted and lose their ability to fight cancer over time. As a result, the cells are less effective in controlling tumors. When NFIL3 was disabled in animal models, the engineered cells remained stronger for longer and were more effective in controlling tumors. This finding suggests that targeting NFIL3 could potentially improve the outcomes of CAR T-cell therapy.

AI summaries can be wrong sometimes—always verify important details using the source article.